Loading
UT
UNITED THERAPEUTICS Corp Stock: price and insider trades · United States
UNITED THERAPEUTICS Corp: what insiders have been doing
Every trade that managers of UNITED THERAPEUTICS Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. Over the twelve months to 18 October 2026, 1,705 filings were filed, from 18 insiders.
No insider bought on the market over the period, while 9 insiders filed 1,444 sales totalling €589.7M. The amount is not disclosed for 44 filings. Benkowitz Michael filed the largest sale, €6.2M, on 30 December 2025.
The median gap between a trade and its publication by SEC (Form 4) is 1 day. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
For context, the typical company on the same exchange (median of 5,814 companies) published 19 filings over the same period, against 1,705 filings here. Looking back to 2016, when coverage begins, insiders filed 1 purchase and 1,571 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 3.18 bn USD and net income at 1.33 bn USD.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
2,370
Thresholds
n/a
Buy Volume
€341
1 ops. · all time
Sell Volume
€623M
1571 ops. · all time
Who traded when
BuySaleMartine A. Rothblatt190 sales
Paul A. Mahon10 sales
Analyst consensus: bullish or bearish?
Analysts rate UNITED THERAPEUTICS Corp Buy (bullish), based on 13 analysts. Average price target: US$651.15.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 2,219 of 24,148 companies
74.6
score / 100
Value58
Quality91
FCF yld4.5%
Earn yld5.8%
EV/EBITDA12.9x
ROE19%
Gross mgn88%
Net mgn42%
Debt/EBITDA0.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$540.03
Analyst consensus
13 analystsBuy
US$321.00Target US$651.15(+21%)US$728.00
Income statement
RevenueUS$3.2B
Gross profitUS$2.8B88% margin
EBITDAUS$1.8B57% margin
Net incomeUS$1.3B41.6% margin
Valuation
PER (trailing)19.3x
PER (forward)15.6x
P/Book3.6x
Beta0.49
Balance sheet & cash
Market capUS$23.2B
Total debtUS$300M
Free Cash FlowUS$1B
Profitability & ownership
ROE19.3%
ROA11.6%
% insiders2.0%
% institutions100.1%
Last declaration on 16 October 2026
Declarations2,370 total
9,500 shares@ US$117.76Common StockSEC:0001106578-26-000165:0
281 shares@ US$540.4764Common StockSEC:0001106578-26-000165:1
1,163 shares@ US$541.5859Common StockSEC:0001106578-26-000165:2
456 shares@ US$542.6793Common StockSEC:0001106578-26-000165:3
371 shares@ US$543.3929Common StockSEC:0001106578-26-000165:4
269 shares@ US$544.7538Common StockSEC:0001106578-26-000165:5
825 shares@ US$545.8747Common StockSEC:0001106578-26-000165:6
601 shares@ US$546.9428Common StockSEC:0001106578-26-000165:7
2,166 shares@ US$547.8268Common StockSEC:0001106578-26-000165:8
2,039 shares@ US$548.8882Common StockSEC:0001106578-26-000165:9
1,009 shares@ US$549.756Common StockSEC:0001106578-26-000165:10
200 shares@ US$550.716Common StockSEC:0001106578-26-000165:11
120 shares@ US$551.50Common StockSEC:0001106578-26-000165:12
8,300 shares@ US$146.03Common StockSEC:0001231589-26-000022:0
268 shares@ US$541.6421Common StockSEC:0001231589-26-000022:1
1,924 shares@ US$542.4914Common StockSEC:0001231589-26-000022:2
1,983 shares@ US$543.5556Common StockSEC:0001231589-26-000022:3
791 shares@ US$544.8485Common StockSEC:0001231589-26-000022:4
2,615 shares@ US$545.6873Common StockSEC:0001231589-26-000022:5
719 shares@ US$546.5608Common StockSEC:0001231589-26-000022:6
8,300 shares@ US$544.30230.020% mcap11.7% of flowCommonSEC144:0001950047-26-010252
9,500 shares@ US$117.760.0048% mcap0.2% of flowCommon StockSEC:0001106578-26-000164:0
40 shares@ US$526.070.0001% mcap0.0% of flowCommon StockSEC:0001106578-26-000164:1
160 shares@ US$530.08750.0004% mcap0.0% of flowCommon StockSEC:0001106578-26-000164:2
120 shares@ US$531.18670.0003% mcap0.0% of flowCommon StockSEC:0001106578-26-000164:3
25 of 2370 declarations
About UNITED THERAPEUTICS Corp
United Therapeutics Corp. (ticker: UTHR) is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States, with its principal headquarters in Silver Spring, Maryland. Founded in 1996, the company has built a focused franchise around pulmonary vascular disease and select rare diseases, giving it a specialized market position with relatively defensive characteristics and a revenue base concentrated in a handful of recognizable brands.
The core business is centered on therapies for pulmonary arterial hypertension (PAH) and, more recently, pulmonary hypertension associated with interstitial lung disease (PH-ILD). Key commercial products include Tyvaso and Tyvaso DPI, Remodulin, Orenitram, and Adcirca. United Therapeutics also markets Unituxin, an FDA-approved antibody therapy for high-risk neuroblastoma, a rare pediatric cancer. This product mix makes the company stand out: it combines orphan-disease exposure with high-value specialty pharmaceuticals, while remaining highly dependent on execution in commercialization, reimbursement access, and intellectual-property protection.
Read moreShow less
From a historical perspective, United Therapeutics was founded in 1996 and has evolved from a niche therapeutics company into a broader biopharmaceutical group. The company emphasizes research, clinical development, and pipeline expansion, which are intended to extend the life cycle of existing franchises and create future growth drivers. Its geographic footprint remains predominantly U.S.-based, with a major operational presence in Silver Spring and an additional hub in Research Triangle Park, North Carolina.
Competitively, United Therapeutics has established a strong position in PAH through brand recognition, clinical expertise, and long-standing relationships with specialist prescribers. Management highlights its capabilities in inhaled and prostacyclin-based therapies, where differentiation depends not only on efficacy but also on ease of administration and patient support. The portfolio is concentrated, but it supports meaningful cash flow visibility and a durable specialty-pharma profile.
Recent highlights include the company’s report in July 2025 of record quarterly financial results, driven by double-digit growth in products such as Tyvaso DPI, nebulized Tyvaso, Orenitram, and Unituxin. Investors should nevertheless monitor pipeline milestones, potential competition across key franchises, and evolving regulatory dynamics. Overall, UTHR remains a high-quality healthcare/pharma name with a niche growth profile, listed on the NASDAQ in the United States and anchored by specialty respiratory and rare-disease franchises.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
